Catalyst
Slingshot members are tracking this event:
AstraZeneca Phase 3 PACIFIC trial—evaluating durvalumab in efficacy for lung cancer—set for data readout in the second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 08, 2017
Occurred Source:
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pacific Trial, Durvalumab, Lung Cancer, Phase 3
